• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TrovaGene, Dana-Farber Cancer Institute collaborate

TrovaGene, Dana-Farber Cancer Institute collaborate

June 17, 2014
CenterWatch Staff

Trovagene has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.

Urine samples will be collected from patients with locally advanced or metastatic melanoma known to harbor driver oncogene mutations. A Dana-Farber oncology team, led by Jason Luke, M.D., will conduct clinical studies designed to monitor oncogene mutations in study subjects based on urinary cell-free DNA as an analytical specimen. Studies will be designed to collect data regarding the clinical status of patients, treatment effect and long-term outcomes of therapy using Trovagene's non-invasive molecular diagnostic technology.

"While precision cancer treatments have made significant advances, current monitoring technologies are either invasive or do not provide specific genomic information to understand how the disease is responding to treatment at the molecular level," said Luke. "Based on study data that Trovagene has presented at medical meetings thus far, we are encouraged that urinary cell-free DNA has potential to offer a non-invasive solution for tracking oncogene mutations during and after treatment, and this may help physicians improve patient outcomes."

Trovagene is engaged in numerous collaborations designed to demonstrate the clinical utility of its precision cancer monitoring platform for the detection of mutational status in cancer patients, and the assessment of tumor dynamics and treatment response over time. To date, the company has processed over 1,000 patient samples under its collaborations, and is focused on developing the clinical evidence to support broad market adoption of its technology.

Antonius Schuh, Ph.D., CEO of Trovagene, said, "With this latest collaboration, we now are working with seven of the top cancer treatment centers in the U.S. to demonstrate the utility of our precision cancer monitoring platform and to integrate our assays into clinical practice. The Dana-Farber collaboration initially is focused on treatment of metastatic melanoma, and we are pleased to be working with Luke and his colleagues to gain greater perspective on how our non-invasive assays can impact the way this disease is managed."

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing